# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Precision BioSciences (NASDAQ:DTIL) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of...
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to ...
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Precision BioSciences (NASDAQ:DTIL) with a Buy rating and anno...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Precision BioSciences (NASDAQ:DTIL) with a Buy and maintains $60...
- Productive collaboration advanced three programs and demonstrated proof of concept of ARCUS for gene excision and gene insert...
Clinical trial sites in the United States, United Kingdom, and Australia will evaluate ECUR-506, an investigational gene editin...